Axsome Therapeutics AXSM Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 92.6%+1.1pp | 92.6%+1.2pp | 91.9%+0.8pp | 91.5%+1.2pp | 91.5%+1.4pp | |
| Operating margin | -24.4%+38.1pp | -26.1%+46.6pp | -37.8%+52.6pp | -46.2%+58.6pp | -62.5%+54.1pp | |
| Net margin | -26.6%+37.8pp | -28.7%+45.8pp | -40.9%+51.0pp | -49.9%+56.0pp | -64.4%+53.7pp | |
| EBITDA margin | -23.5%+37.5pp | -25%+45.9pp | -36.6%+51.8pp | -44.9%+57.6pp | -60.9%+52.9pp | |
| Free cash flow margin | -10.2%+17.3pp | -14.9%+18.5pp | -18.2%+21.0pp | -24.5%+33.2pp | -27.5%+49.5pp | |
| Returns | ||||||
| Return on equity | -349.4%-67.2pp | -252.1%-20.5pp | -275.5%-104pp | -280.7%-119pp | -282.2%-50.5pp | |
| Return on assets | -28.7%+20.0pp | -29.1%+20.5pp | -37.3%+16.2pp | -41.6%+11.6pp | -48.7%+14.7pp | |
| Efficiency | ||||||
| Asset turnover | 1.1×+0.3× | 1×+0.3× | 0.9×+0.3× | 0.8×+0.3× | 0.8×+0.2× | |
| Inventory turnover | 2.2×-0.1× | 2.2×0.0× | 2.4×-0.1× | 2.5×+0.2× | 2.3×+0.2× | |
| Liquidity | ||||||
| Current ratio | 1.4×-0.6× | 1.6×-0.6× | 1.6×-0.9× | 1.6×-0.9× | 2×-1.2× | |
| Quick ratio | 1.3×-0.6× | 1.5×-0.6× | 1.5×-0.9× | 1.5×-0.9× | 2×-1.1× | |
| Cash ratio | 0.7×-0.5× | 0.9×-0.5× | 0.9×-0.8× | 0.9×-0.8× | 1.2×-1.1× | |
| Leverage | ||||||
| Debt-to-equity | 4×+0.1× | 2.5×-0.9× | 3×+0.9× | 3×+1.1× | 4×+2.7× | |
| Debt-to-assets | 0.3×0.0× | 0.3×0.0× | 0.3×0.0× | 0.3×0.0× | 0.4×0.0× | |
| Per Share | ||||||
| Book value per share | $1.07-2.1% | $1.77+49.2% | $1.47-23.6% | $1.48-31.6% | $1.09-64.2% | |
| Valuation | ||||||
| Market capitalization | $8.65B+52.0% | $9.21B+125% | $6.06B+41.8% | $5.13B+34.6% | $5.69B+50.4% | |
| Enterprise value | $8.56B+52.9% | $9.1B+129% | $5.95B+43.8% | $5.05B+36.7% | $5.6B+53.8% | |
| Price / sales | 12.2×-1.0× | 14.4×+3.8× | 10.8×-1.8× | 10.4×-2.7× | 13.2×-1.9× | |
| Price / book | 158.4×+51.5× | 104.3×+32.4× | 82.2×+36.2× | 70.2×+33.2× | 106.9×+80.6× | |
| EV / sales | 12.1×-0.9× | 14.3×+3.9× | 10.6×-1.6× | 10.2×-2.5× | 13×-1.5× | |
| Free cash flow yield | -0.8%+1.3pp | -1%+2.1pp | -1.7%+1.4pp | -2.4%+2.0pp | -2.1%+3.0pp | |
| Earnings yield | -2.2%+2.7pp | -2%+5.0pp | -3.8%+3.5pp | -4.8%+3.3pp | -4.9%+2.9pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Axsome Therapeutics's profit margins?
- Axsome Therapeutics (AXSM) runs a 92.6% gross margin and a -24.4% operating margin, with a -26.6% net margin.
- Where do Axsome Therapeutics's ratios come from?
- Every ratio is computed from Axsome Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
